With this payment, Critical Therapeutics has now received a total of $12 million from Dey as part of the companies’ co-promotion agreement. Critical Therapeutics received $3 million from Dey upon signing the co-promotion agreement in the first quarter of 2007 and $4 million upon the FDA’s approval of Zyflo CR in the second quarter of 2007.
Frank Thomas, president and CEO of Critical Therapeutics, said: “We are seeing steady growth in new prescriptions of Zyflo CR and are encouraged by the progress we have achieved since the launch of Zyflo CR in late September. Critical Therapeutics and Dey’s combined sales forces of 240 representatives are promoting Zyflo CR to approximately 18,000 allergists, pulmonologists and primary care physicians across the country.”